16 September 2026 editorial review · Trial
Sequential cord-blood stem cells and islets in monogenic immunodeficiency T1D: review notes
These notes document the scope actually reviewed, including source-access limits. They are not independent clinical certification or a guarantee that every claim was verified.
Read the trial evidence page →Primary-agent trial review — 16 September 2026
Assessment: Clarified rare monogenic immune-disorder population; does not represent ordinary autoimmune T1D.
Registry: NCT03835312; RECRUITING; updated 2026-03-17; enrollment 50 (ESTIMATED); results not posted.
Endpoint comparison: Concentration of serum C-peptide (from the completion of treatment to 3 months); Concentration of serum C-peptide (from the completion of treatment to 3 years).
Sources for this record: NCT03835312: Sequential cord-blood stem cells and islets in monogenic immunodeficiency T1D (registry).
Limits: Source access and review depth vary. Registry fields establish the registered study, not clinical benefit, product approval or current local access. Cited-source reachability alone was not treated as verification of its claims.